Abstract:Lecithin:cholesterol acyltransferase (LCAT) exhibits α-activity on high-density and β-activity on low-density lipoproteins. However, the molecular determinants governing LCAT activation by different apolipoproteins remain elusive. Uncovering these determinants would offer the opportunity to design and explore advanced therapies against dyslipidemias. Here, we have conducted coarse-grained and all-atom molecular dynamics simulations of LCAT with nanodiscs made with α-helical amphiphilic peptides either derived from apolipoproteins A1 and E (apoA1 and apoE) or apoA1 mimetic peptide 22A that was optimized to activate LCAT. This study aims to explore what drives the binding of peptides to our previously identified interaction site in LCAT. We hypothesized that this approach could be used to screen for binding sites of LCAT in different apolipoproteins and would provide insights to differently localized LCAT activities. Our screening approach was able to discriminate apoA1 helixes 4, 6, and 7 as key contributors to the interaction with LCAT supporting the previous research data. The simulations provided detailed molecular determinants driving the interaction with LCAT: the formation of hydrogen bonds or salt bridges between peptides E4 or D4 and LCAT S236 or K238 residues. Additionally, salt bridging between R7 and D73 was observed, depending on the availability of R7. Expanding our investigation to diverse plasma proteins, we detected novel LCAT binding helixes in apoL1, apoB100, and serum amyloid A. Our findings suggest that the same binding determinants, involving E4 or D4 -S236 and R7-D73 interactions, influence LCAT β-activity on low-density lipoproteins, where apoE and or apoB100 are hypothesized to interact with LCAT. Atherosclerotic cardiovascular disease is caused by the accumulation of cholesterol in arteries. A developing class of therapies against it attempt to promote the efficiency of high-density lipoprotein (HDL), which removes cholesterol from peripheral cells. Importantly, this includes cholesterol-laden macrophages, also known as foam cells, present in atherosclerotic lesions. In this context, one strategy focuses on improving the cholesterol carrying capacity of HDL by improving the enzymatic activity of lecithin:cholesterol acyltransferase (LCAT). Although LCAT remodels HDL to accept more cholesterol, it also remodels low-density lipoprotein (LDL), which has an opposite effect to HDL. In other words, LDL brings cholesterol to peripheral cells. We hypothesize that this may be part of the reason why LCAT activation hasn't shown clinical success thus far. In order to investigate this, we must selectively inhibit LCAT's activity on LDL, which in turn requires us to know which amino acids take part in the LCAT-HDL and LCAT-LDL interactions. In this article, we've used molecular dynamics simulations to reveal these amino acids. This information will be useful in the optimization of LCAT and HDL based therapies against atherosclerosis as well as in the design of HDL-like drug delivery systems whose properties are affected by LCAT.

Physiological Variations in Plasma Sphingomyelin (SM) Inversely Correlate with Lecithin‐cholesterol Acyltransferase (LCAT) Activity

Regulation of Plasma Cholesterol Esterification by Sphingomyelin: Effect of Physiological Variations of Plasma Sphingomyelin on Lecithin-Cholesterol Acyltransferase Activity

Increased sphingomyelin content of plasma lipoproteins in apolipoprotein E knockout mice reflects combined production and catabolic defects and enhances reactivity with mammalian sphingomyelinase.

Impaired regulation of sterol regulatory element binding protein 2 in cholesterol gallstone-susceptible mice.

Abstract 410: Effect of Total Sphingomyelin Synthase Activity on Low Density Lipoprotein Catabolism

Plasma sphingomyelin level as a risk factor for coronary artery disease.

Liver-specific Deficiency of Serine Palmitoyltransferase Subunit 2 Decreases Plasma Sphingomyelin and Increases Apolipoprotein E Levels.

Impact of Sphingomyelin Levels on Coronary Heart Disease and Left Ventricular Systolic Function in Humans

Sphingomyelin Synthase 2 is One of the Determinants for Plasma and Liver Sphingomyelin Levels in Mice

The Effect of Dietary Sphingolipids on Plasma Sphingomyelin Metabolism and Atherosclerosis.

Effect of Total SMS Activity on LDL Catabolism in Mice.

Influence of vesicle surface composition on the interfacial binding of lecithin:cholesterol acyltransferase and apolipoprotein A-I

Sphingomyelin Biosynthesis: Its Impact on Lipid Metabolism and Atherosclerosis

Co-determination of Sphingomyeline and Cholesterol in Cellular Plasma Membrane in Sphingomyeline-depletion Induced Cholesterol Efflux.

Effect of Phospholipid on the Ability of HDL3 Mediated Cholesterol Efflux from Rat Skin Fibroblasts

Reduced cholesteryl ester transfer in plasma of patients with lipoprotein lipase deficiency

Systematic evaluation of lecithin:Cholesterol acyltransferase binding sites in apolipoproteins via peptide based nanodiscs: Regulatory role of charged residues at positions 4 and 7

Effects of Recombinant Human Lecithin Cholesterol Acyltransferase on Lipoprotein Metabolism in Humans

Further evaluation of plasma sphingomyelin levels as a risk factor for coronary artery disease

Effect of Liver Total Sphingomyelin Synthase Deficiency on Plasma Lipid Metabolism.

Secretory Sphingomyelinase, A Product of the Acid Sphingomyelinase Gene, Can Hydrolyze Atherogenic Lipoproteins at Neutral Ph - Implications for Atherosclerotic Lesion Development